Article

FDA official shares 11 steps of bringing products to market

Ophthalmologists should remember 11 steps when attempting to bring products to the market, said Malvina Eydelman, MD, director, division of ophthalmic and ENT devices, Center for Devices and Radiological Health, FDA, in a mini-symposium on glaucoma pubic policy during the American Glaucoma Society annual meeting. Dr. Eydelman provided the perspective of the regulator.

Ophthalmologists should remember 11 steps when attempting to bring products tothe market, said Malvina Eydelman, MD, director, division of ophthalmic and ENT devices, Centerfor Devices and Radiological Health, FDA, in a mini-symposium on glaucoma public policy duringthe American Glaucoma Society annual meeting. Dr. Eydelman provided the perspective of theregulator.The 11 steps:

  • Determine whether the product is a medical device, drug, biologic, or a combination product.
  • Determine the device classification (Class I, Class II, or Class III) at http://www.fda.gov/cdrh/devadvice/3131.html.
  • Check to see whether FDA guidance, which represents the agency's current thinking on thematter, exists at http://www.fda.gov/cdrh/guidance.html. FDA guidance is not binding, Dr.Eydelman said.
  • Check to see whether recognized standards exist.
  • Design an appropriate clinical trial. "Taking time to plan and think is the biggestrecommendation," she said.
  • Determine the location of the clinical trial.
  • Select qualified investigators appropriate for the particular product.
  • Provide adequate training to those who will be involved with the study, stressing theimportance of the informed consent process.
  • Optimize the dataset.
  • Ensure adequate monitoring.
  • Ensure investigator compliance.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.